Literature DB >> 10182437

The importance of the physician in the generic versus trade-name prescription decision.

J K Hellerstein1.   

Abstract

I examine the importance of physicians in the process by which patients receive either trade-name or generic drugs. Using a dataset on physicians, their patients, and the multisource drugs prescribed, I find that almost all physicians prescribe both types of drugs to their patients, but some physicians are more likely to prescribe generic drugs while other physicians are more likely to prescribe trade-name drugs. Very little of the prescription decision can be explained by observable characteristics of individual patients, but all of the evidence indicates that physicians are indeed an important agent in determining whether patients receive either trade-name or generic drugs.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10182437

Source DB:  PubMed          Journal:  Rand J Econ        ISSN: 0741-6261


  37 in total

1.  Dispensing rates of four common hearing aid product features: associations with variations in practice among audiologists.

Authors:  Earl E Johnson; Todd A Ricketts
Journal:  Trends Amplif       Date:  2010-05-10

2.  Economic consequences of underuse of generic drugs: evidence from Medicaid and implications for prescription drug benefit plans.

Authors:  Michael A Fischer; Jerry Avorn
Journal:  Health Serv Res       Date:  2003-08       Impact factor: 3.402

3.  Has the European union achieved a single pharmaceutical market?

Authors:  Aysegul Timur; Gabriel Picone; Jeffrey DeSimone
Journal:  Int J Health Care Finance Econ       Date:  2011-10-09

4.  Specification Issues in a Big Data Context: Controlling for the Endogeneity of Consumer and Provider Behaviours in Healthcare Treatment Effects Models.

Authors:  William H Crown
Journal:  Pharmacoeconomics       Date:  2016-02       Impact factor: 4.981

5.  Retailing policies for generic medicines.

Authors:  Susana Narciso
Journal:  Int J Health Care Finance Econ       Date:  2005-06

6.  Competitive pricing within pharmaceutical classes: evidence on "follow-on" drugs in Germany 1993-2008.

Authors:  Michael T Mueller; Alexander Frenzel
Journal:  Eur J Health Econ       Date:  2013-12-27

7.  Regulated medical fee schedule of the Japanese health care system.

Authors:  Makoto Kakinaka; Ryuta Ray Kato
Journal:  Int J Health Care Finance Econ       Date:  2013-09-26

8.  Pricing of prescription drugs and its impact on physicians' choice behavior.

Authors:  Chen Miao-Sheng; Shih Yu-Ti
Journal:  Health Care Manag Sci       Date:  2008-09

9.  Potential savings from an evidence-based consumer-oriented public education campaign on prescription drugs.

Authors:  Julie M Donohue; Michael A Fischer; Haiden A Huskamp; Joel S Weissman
Journal:  Health Serv Res       Date:  2008-05-13       Impact factor: 3.402

10.  Generic substitution: micro evidence from register data in Norway.

Authors:  Dag Morten Dalen; Kari Furu; Marilena Locatelli; Steinar Strøm
Journal:  Eur J Health Econ       Date:  2010-03-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.